Generic Medicine Info
Recent MI, arrhythmias, severe liver disease, manic phase. Porphyria. Lactation.
Special Precautions
CV disease, history of epilepsy, hepatic impairment, hyperthyroidism, pheochromocytoma, history of mania, psychoses, close-angle glaucoma, history of urinary retention, concurrent electroconvulsive therapy, DM. Avoid abrupt withdrawal. May impair ability to drive and operate machines. Pregnancy. Elderly and children.
Adverse Reactions
Marked antimuscarinic and CV effects. Dry mouth, sedation, blurred vision, constipation, difficulty in micturition, nausea, sweating, tremor, hypersensitivity reactions, behavioral disturbances, sexual dysfunction, blood sugar changes, increased appetite or wt gain. Testicular enlargement, gynecomastia, galactorrhoea. Convulsion, movement disorders, dyskinesias. Fever and blood disorders.
Drug Interactions
Plasma conc and effects may be enhanced by cimetidine, diltiazem, disulfiram, methylphenidate, ritonavir and verapamil. Side-effects may be increased by adrenaline, amiodarone, general anaesthetics, SSRIs, antihistamines, antimuscarinics, antipsychotics, anxiolytics and hypnotics, clozapine, disopyramide, diuretics, flecainide, MAOIs, moclobemide, moxifloxacin, nefopam, nicorandil, noradrenaline, pimozide, procainamide, propafenone, quinidine, selegiline, sibutramine, sotalol, terfenadine, thioridazine and tramadol. Effects of adrenergic neuron blocker, clonidine, barbiturates, nitrates, and primidone are reduced while effects of baclofen, opioid analgesics and thyroid hormones are enhanced. Carbamazepine and rifampicin may increase metabolism while its effects may be antagonised by oestrogens.
Potentially Fatal: Concomitant use with brimonidine, entacapone, artemether with lumefantrine, or sibutramine should be avoided.
Lab Interference
Abnormal LFT.
Description: Amineptine is a TCA. It selectively inhibits the reuptake of dopamine and to a lesser extent norepinephrine, thus exerting a powerful and fast-acting antidepressant effect.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Amineptine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in